Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

to placebo or teriflunomide, 7mg or 14mg, once daily. The primary endpoint was annualized relapse rate defined as the number of confirmed relapses per patients-year. The key secondary endpoint was the time to disability progression measured by EDSS. Safety and tolerability evaluations were based on treatment emergent adverse events, physical examinations, vital signs and laboratory investigations.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, unpredictable and progressively disabling disease. Patients with MS typically are diagnosed at a young age and they face a lifetime of uncertainty with gradually declining health. Today, over two million people around the world suffer from MS. MS is the result of damage to myelin, a protective sheath surrounding nerve fibres of the central nervous system. When myelin is damaged, this interferes with messages between the brain and other parts of the body. Multiple sclerosis is a very variable condition and the symptoms depend on which areas of the central nervous system have been affected. There is no definite pattern to MS and everyone with MS has a different set of symptoms, which vary from time to time and can change in severity and duration, even in the same person. Management of MS is complex; early intervention in the pathological process is recommended in order to delay disease progression or at least, slow it down. A complex support system is required for the care of MS patients, including health and social services, as well as various healthcare professionals. Although there is no known cure for multiple sclerosis, several therapies are proven to be helpful but there remains an unmet need for new oral therapies with an acceptable benefit/risk profile.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... a Florida State University research team has led to ... emit white light, and convert photon energy directly to ... butterfly. , Biwu Ma, associate professor in the Department ... of Engineering, created the molecule in a lab about ... his creation has many other unique capabilities. , For ...
(Date:8/28/2014)... 2014 PrimeSource Building Products, Inc., ... SoundConnect to support their communication needs ... and web conferencing platform GlobalMeet powered by SoundConnect. ... needs. SoundConnect delivers award winning “results driven” ... Products will be utilizing GlobalMeet powered by ...
(Date:8/27/2014)... 2014 Green & Grow Inc. (GGI) ... funding and secured Otter Capital as a significant new ... commercialization of GGI’s Agriplier™ technology, building on recent compelling ... “Since our first meeting, we have been impressed with ... space,” said Alan Sobba, President and CEO of GGI. ...
(Date:8/27/2014)... MSC , a healthcare performance improvement company advancing clinical ... Mary Beth Loesch to President and CEO. ... companies for rapid growth and market expansion, Loesch joined ... Development and Healthcare. In that role, she oversaw MSC,s ... corporate strategy and marketing. Previously, Loesch served as Senior ...
Breaking Biology Technology:Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3MSC names Mary Beth Loesch President and CEO 2
... ,S-HERTOGENBOSCH, The Netherlands , April 28, 2010 , Pepscan, ... for the generation of immune therapeutics, today,announced that it reached a ... Under the terms of the,agreement Pepscan will receive an undisclosed cash ... , , ...
... The Netherlands , April 27, 2010 Immunovo,BV, a new ... insights in oncology to develop novel,therapeutics, secures seed funding from Dutch venture ... ... - Immunovo BV, a new,biotechnology company developing a novel technology platform for ...
... April 27 The Johns Hopkins University School of Medicine ... collaborative program to advance the development and use of stem cells in therapies ... train researchers to use stem cells and foster joint research projects. , ... The collaborative program will encompass training for ...
Cached Biology Technology:Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio 2Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio 3Immunovo BV- A New Biotechnology Company is Announced 2The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 2The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 3The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 4The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 5
(Date:8/28/2014)... million kilometres of new roads will be built worldwide ... Earth,s last wildernesses, where they bring an influx of ... an ambitious study has created a ,global roadmap, for ... balance the competing demands of development and environmental protection. ... that estimates that natural importance of ecosystems and a ...
(Date:8/28/2014)... California, and Alaska totaled 515 million board feet in ... of more than 10 percent compared to the first ... Research Station reported today. During this same period, West ... million board feet. , The total value of these ... $390 million in the same quarter, while the total ...
(Date:8/27/2014)... single fungal cell or bacterial colony exerts on a plant ... role in setting up some of the most fundamental symbiotic ... much of a stretch to say that plants may have ... the touch of beneficial fungi, according to a new study ... University of Wisconsin-Madison. , "Many people have studied how ...
Breaking Biology News(10 mins):Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3West coast log exports up, lumber exports down in second quarter of 2014 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3
... could become even more prevalent and destructive as climate change ... more than 150 years. Writing in the journal ... study say that non-native plants, and especially invasive species, appear ... able to adjust the timing of annual activities like flowering ...
... Charles Drew University of Medicine and Science is investigating the ... therapy for cancer. Dr. Mamdooh Ghoneum presented his findings ... Mechanism," sponsored by the American Association for Cancer Research (AACR) ... "The central focus of the meeting is cell death ...
... A 60-million-year-old relative of crocodiles described this week by ... Vertebrate Paleontology was likely a food source for ... Working with scientists from the Smithsonian Tropical Research ... Natural History on the UF campus found fossils of ...
Cached Biology News:Invasive plants are beneficiaries of climate change in Thoreau's woods 2Charles Drew cancer studies with yeast yield excellent results 2UF researchers: Ancient crocodile relative likely food source for Titanoboa 2UF researchers: Ancient crocodile relative likely food source for Titanoboa 3